Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Paul Macleod
Observed name:
Paul MacLeod
OpenAlex ID:
A5089340366
Life-years and quality-adjusted life-years with belantamab mafodotin, bortezomib, and dexamethasone vs alternative regimens in patients with Relapsed/Refractory multiple myeloma who received ≥1 prior line of therapy
2025
·
Attaya Suvannasankha
, Benga Kazeem
, et al.
·
Blood
PDF
EE282 Quality-Adjusted Life Year (QALY) Results From a Cost-Effectiveness Model for Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Relapsed/Refractory Multiple Myeloma (RRMM)
2025
·
Martin Kaiser
, Attaya Suvannasankha
, et al.
·
Value in Health
Show more works
View as search
Works count:
2
Citation count:
H-index:
I10-index:
Year
Topic
Type
